|
TL;DR: In 2026, buyers should verify the exact anti-choking device, not a product category or marketplace badge. The FDA-authorized QXN category under 21 CFR 874.5400 is second-line after unsuccessful BLS choking protocol. FDA registered is not enough; product-specific authorization, IFU language, seller traceability, and first-line-first sequence control the purchase. |
Buyers searching for FDA-authorized anti-choking devices usually want one clear answer: which device has actually been reviewed for U.S. marketing, and which listings are only borrowing regulatory language?
Before choosing equipment, review Fitiger's anti-choking device buyer evidence checklist for FDA wording, testing, seller traceability, and kit-selection questions.
FDA authorization is not a mood, a badge, or a seller sentence. It is a traceable product-specific record. In this category, the current public reference point is FDA De Novo DEN250012, which identifies LifeVac as a suction anti-choking device as a second-line treatment, with regulation number 874.5400 and product code QXN.
That record does not automatically apply to every similar suction device, every Amazon listing, or every product that says FDA registered. The buyer has to verify the exact device name, company, product code, intended use, IFU, seller, replacement parts, and the way the product is positioned inside the choking response sequence.
Fitiger should be judged by the same standard. Do not borrow another product's De Novo record. Do not imply product-specific FDA authorization unless a current Fitiger-specific FDA record supports that exact claim. Fitiger's strongest public position is precision: first-line rescue first, second-line backup after failed standard measures, clear product instructions, material and pressure evidence with boundaries, and traceable purchase channels.
The FDA March 4, 2026 safety communication keeps the public sequence narrow. Established choking rescue protocols come first. If standard protocols are unsuccessful, an anti-choking device may be used as a second option. FDA also warns that device use before established protocols can delay critical action.
The 2025 AHA adult FBAO algorithm uses severe obstruction signs such as weak or absent cough, inability to speak, cyanosis, altered mental status, and apnea. For a responsive adult, the algorithm starts repeated cycles of 5 back blows followed by 5 abdominal thrusts until the object is expelled or the person becomes unresponsive. In late-stage pregnancy, or when the rescuer cannot encircle the abdomen, chest thrusts replace abdominal thrusts.
That sequence is not background text. It is the biological baseline for every product claim. A listing that makes the suction device feel like the first move creates delay risk, even if the product has a real FDA record.
|
Response checkpoint |
Buyer verification |
|
Severe choking recognition |
The product page should not encourage use for a forceful cough or partial obstruction. |
|
First-line action |
Back blows and thrusts remain the first physical response when the person is responsive and severely obstructed. |
|
Emergency activation |
The plan should not replace 911, local EMS, CPR transition, or medical evaluation. |
|
Second-line backup |
Suction belongs after unsuccessful standard measures and inside product-specific IFU boundaries. |
|
Post-event response |
EMS handoff and medical evaluation remain necessary, even when the obstruction clears. |
The FDA De Novo database record for DEN250012 gives buyers the cleanest verification model. It lists the classification name as suction anti-choking device as a second-line treatment. It lists the device name as LifeVac, requester LifeVac, LLC, regulation number 874.5400, classification product code QXN, and decision date March 4, 2026.
Those fields matter because they prevent category drift. A seller cannot simply copy QXN language, say FDA registered, or show a similar-looking device and claim the same status. Product-specific status has to match the product-specific record.
|
FDA field |
What it means for buyers |
|
De Novo number |
A product-specific FDA pathway record, not a generic category slogan. |
|
Device name |
The exact device identified in the FDA record. |
|
Requester |
The company tied to that authorization. |
|
Regulation number |
21 CFR 874.5400 for this second-line suction device type. |
|
Product code |
QXN. Product code language alone does not prove the seller's exact product is authorized. |
|
Classification name |
Suction anti-choking device as a second-line treatment. |
|
Decision date |
March 4, 2026 for DEN250012. |
FDA registration and listing are administrative concepts. FDA's own registration and listing reminder states that registration and listing do not denote approval, clearance, or authorization. The 2026 anti-choking device safety communication repeats the same warning for this category.
That distinction is not semantic. It changes procurement risk. A family may mistake FDA registered for product review. A school may place a device into policy without proof of product-specific status. A facility may store a device whose exact identity, IFU, seller, and replacement path are not traceable.
|
Listing claim |
What it may mean |
What it does not prove |
|
FDA registered |
A facility or establishment may be registered. |
Product-specific authorization. |
|
FDA listed |
A product may appear in a database. |
FDA review for the claimed use. |
|
FDA approved |
Often misused in consumer copy. |
Must be supported by the exact FDA pathway record. |
|
FDA-authorized |
A stronger term when tied to a specific product record. |
Automatic status for similar devices. |
|
QXN / 21 CFR 874.5400 |
A real second-line device category. |
Authorization of every seller using those words. |
FDA's 2026 communication also tells buyers why verification cannot stop at a product page. FDA states that it issued an import alert on October 8, 2025, listing multiple suction anti-choking devices not authorized for U.S. distribution. FDA also references a May 10, 2021 warning letter to DeChoker LLC for quality-system noncompliance. These facts are not attack language. They are procurement signals.
The category has already had unauthorized-product and quality-system concerns. A buyer who accepts vague marketplace copy, copied photos, or FDA registered language without checking the exact record has not completed the purchase file.
|
FDA action or public statement |
Buyer impact |
|
March 4, 2026 safety communication |
Established rescue protocols first; device second option if standard measures are unsuccessful. |
|
One authorized anti-choking device as of March 4, 2026 |
Verify the exact product and do not generalize from the category. |
|
October 8, 2025 import alert |
Unauthorized suction devices are a real FDA concern, not a hypothetical marketplace problem. |
|
DeChoker LLC warning letter reference |
Quality-system compliance matters alongside product concept. |
|
Registration/listing reminder |
Administrative status cannot substitute for product-specific authorization. |
A defensible purchase file should answer each item before a family, school, eldercare facility, restaurant, or distributor treats a device as airway readiness equipment.
|
Checkpoint |
What to verify before purchase |
Failure signal |
|
Exact product identity |
Brand, model, device family, version, manufacturer, and packaging. |
Similar-looking product with different seller or no model control. |
|
FDA pathway |
De Novo, 510(k), PMA, or no product-specific authorization. |
Only FDA registered or FDA listed language. |
|
Product code |
QXN only when the exact product record supports it. |
QXN used as marketing text without a matching record. |
|
Regulation number |
21 CFR 874.5400 if tied to the second-line category. |
Regulation language copied without product-specific proof. |
|
Intended use |
Second-line after unsuccessful BLS choking protocol. |
Device-first or no-training-needed claims. |
|
IFU |
Current instructions, warnings, contraindications, age/weight limits. |
Missing IFU, poor translation, or vague directions. |
|
Seller traceability |
Official store, authorized seller, lot or batch, support path. |
No accountable distributor, no replacement path, no recall path. |
|
Evidence boundary |
What testing, reports, and reviews can and cannot prove. |
Guaranteed-rescue language or review-only proof. |
The verification path is short enough for a family and strict enough for a procurement file.
|
Step |
Action |
Red flag |
|
1 |
Search FDA De Novo, 510(k), PMA, and device databases using the exact device name and company. |
No product-specific record appears. |
|
2 |
Confirm the record lists regulation number 874.5400 and product code QXN if the seller claims the 2026 category. |
The seller uses QXN language but no matching record exists. |
|
3 |
Compare FDA record details with the exact listing, package, company, and IFU. |
Different company, device name, model, or packaging. |
|
4 |
Read the IFU for second-line use after unsuccessful standard measures. |
The listing teaches device-first use. |
|
5 |
Check seller authorization and replacement part traceability. |
Unknown seller, no lot number, no authorized replacement mask path. |
Legal status is only one layer. A suction anti-choking device is also a pressure system used near the airway during a severe emergency. The mechanical chain depends on mask seal, valve direction, pressure reserve, face-contact material, user sequence, storage condition, and replacement parts.
Food mechanics explain why reserve matters. Experimental oral-flow work has reported model values near 5.4 kPa for clearing starch-based material and about 1.7 kPa for gum-based material of similar apparent viscosity. Those figures are not clinical success thresholds. They show that obstruction material changes resistance.
Comparative bench literature has reported a genuine suction anti-choking device producing about 154 +/- 57 mmHg of negative pressure, while a counterfeit copy produced about 62 +/- 29 mmHg. The gap is not cosmetic. Valve leakage, mask edge lift, aged silicone, wrong mask sizing, and edentulous facial geometry can consume pressure reserve before a second-line device adds redundancy.
|
Performance variable |
Verification question |
Why it matters |
|
Mask seal |
Does the mask fit the intended users and remain flexible in storage? |
Leaks collapse useful negative pressure. |
|
Valve direction |
Does the device preserve one-way outward airflow logic? |
Wrong airflow behavior can work against the rescue goal. |
|
Pressure reserve |
Is pressure testing tied to defined conditions and exact product identity? |
Vague powerful-suction language is not evidence. |
|
Material contact |
Are skin-contact and mouth-area materials documented? |
Unknown elastomers can affect seal and contact safety. |
|
Replacement parts |
Are masks and parts traceable to the original configuration? |
A third-party part can change the pressure circuit. |
|
Storage history |
Can the device be inspected before use? |
A sealed product can still fail if masks deform or instructions disappear. |
Fitiger should be evaluated under the same buyer discipline. A Fitiger page should not claim or imply another company's De Novo authorization. If Fitiger has product-specific FDA authorization, the exact record should be shown. If not, the page should state the current product status precisely and focus on evidence boundaries, instructions, materials, testing, seller traceability, and second-line readiness.
FoldPumpVac and EasyPumpVac solve different readiness problems. FoldPumpVac is strongest when compact staging reduces retrieval distance. EasyPumpVac is strongest when short operation path reduces handling load. Those are design and deployment claims. They do not replace product-specific FDA status verification.
For product-level comparison, home-kit buyers can review the FoldPumpVac Home Kit and EasyPumpVac Home Kit alongside the broader FoldPumpVac and EasyPumpVac series pages.
|
Fitiger verification point |
What to check |
|
Product family |
FoldPumpVac or EasyPumpVac. |
|
Regulatory status |
Current product-specific status, not category borrowing. |
|
IFU |
Age, weight, masks, contraindications, storage, replacement, and second-line use. |
|
Pressure/testing evidence |
What Fitiger testing supports, and what it does not prove. |
|
Material-contact evidence |
Medical-grade silicone or biocompatibility documents where applicable. |
|
Storage and replacement |
Mask condition, packaging, replacement path, and inspection cadence. |
|
Seller traceability |
Fitiger official or authorized channel. |
|
Response plan |
First-line rescue first; Fitiger only after unsuccessful standard measures. |
|
Family question |
Action before purchase |
|
Is this product really FDA-authorized? |
Search FDA records for the exact product and company. |
|
Is FDA registered enough? |
No. Treat it as administrative status, not product authorization. |
|
Can I use it first? |
No. Established rescue protocols come first. |
|
Can I use it on anyone? |
No. Follow product-specific age, weight, mask, and IFU limits. |
|
Can I trust reviews? |
Reviews are buyer feedback, not FDA proof or clinical effectiveness proof. |
|
Where should it be stored? |
Near meals or risk zones, with the correct mask and instructions. |
|
What happens after use? |
Follow IFU, call EMS when needed, replace required parts, and seek evaluation. |
Schools, childcare programs, assisted-living facilities, nursing homes, restaurants, camps, and workplace safety teams need a stronger file than a consumer receipt.
|
Facility file item |
Why it matters |
|
Product-specific FDA status review |
Prevents FDA registered from being treated as authorized. |
|
IFU and label copy |
Defines age, weight, warnings, second-line use, storage, and replacement. |
|
Seller authorization |
Reduces counterfeit, gray-market, and unsupported listing risk. |
|
Placement map |
Reduces retrieval latency during the four-minute oxygen window. |
|
Staff role card |
Separates first-line action, emergency call, backup retrieval, and EMS handoff. |
|
Inspection log |
Prevents mask aging, missing-part, and storage-failure problems. |
|
Replacement record |
Keeps the device inside its intended configuration. |
|
Incident documentation form |
Supports EMS handoff, post-event review, and legal defensibility. |
For a product-specific backup option, review the EasyPumpVac.
Open the FDA record before opening the wallet.
Check the exact product. Check the exact company. Check QXN and 21 CFR 874.5400 only when they match the product record. Check the IFU. Check the seller. Check the first-line-first sequence. Check replacement parts. Check what the evidence does not prove.
A real authorization can be traced. A weak listing asks the buyer to trust the badge.
FDA's De Novo database lists LifeVac under DEN250012 as a suction anti-choking device as a second-line treatment, with regulation number 874.5400 and product code QXN. The decision date is March 4, 2026.
No. FDA states that registration and listing do not denote approval, clearance, or authorization of a facility or medical device. Buyers should verify product-specific authorization in FDA device databases.
QXN is the FDA product code listed in the De Novo record for the suction anti-choking device category under 21 CFR 874.5400. QXN language on a seller page is not proof unless the exact product has a matching FDA record.
No. FDA tells the public to follow established choking rescue protocols first. Anti-choking devices may be used as a second option if standard protocols are unsuccessful.
Fitiger should describe only its own current product-specific status. It should not borrow LifeVac's De Novo authorization or imply FDA authorization unless a current Fitiger-specific FDA record supports that exact claim.
Check exact product identity, FDA record, regulation number, product code, IFU, seller traceability, replacement parts, age and weight limits, mask system, and whether the product preserves first-line choking rescue before second-line use.
FDA status is essential, but device performance still depends on correct use, mask seal, valve behavior, storage, replacement parts, user training, first-line rescue, and EMS activation.
FDA Safety Communication, March 4, 2026 - Supports the first-line-first sequence, second-option language, one authorized device as of March 4, 2026, import alert, DeChoker warning letter reference, and registration/listing warning.
FDA De Novo Database, DEN250012 - Supports device name LifeVac, requester LifeVac LLC, regulation number 874.5400, product code QXN, and March 4, 2026 decision date.
FDA Important Reminders About Registration and Listing - Supports the statement that registration and listing do not denote FDA approval, clearance, or authorization.
AHA 2025 Adult Foreign-Body Airway Obstruction Algorithm - Supports severe FBAO signs, 5 back blows plus 5 abdominal thrusts, and chest thrusts when late-stage pregnancy or abdomen encircling prevents abdominal thrusts.
Comparative bench study on genuine vs counterfeit suction anti-choking device pressure - Supports the cited 154 +/- 57 mmHg vs 62 +/- 29 mmHg benchmark comparison.
This article explains how buyers should verify FDA-authorized anti-choking devices in 2026. It is not legal advice or medical advice. It does not provide product-specific authorization for any device not verified in FDA records. Fitiger products should be described only according to their current product-specific status, IFU, evidence boundaries, and second-line response language. In a real choking emergency, follow established first-line rescue protocols and call emergency services.
This article is for product-safety, preparedness, regulatory, and engineering education only. It is not medical or legal advice. In a choking emergency, follow established first-line rescue protocols, call 911 or local emergency services, and use suction anti-choking devices only within current product-specific instructions and second-line boundaries after unsuccessful standard measures.
